The task of epitope discovery and vaccine design is increasingly reliant on bioinformatics
analytic tools and access to depositories of curated data relevant to immune reactions and …

Immunotherapies are yielding effective treatments for several previously untreatable
cancers. Still, the identification of suitable antigens specific to the tumour that can be targets …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

Many SARS-CoV-2 variants with naturally acquired mutations have emerged. These
mutations can affect viral properties such as infectivity and immune resistance. Although the …

Human leukocyte antigen (HLA) can recognize and bind foreign peptides to present them to
specialized immune cells, then initiate an immune response. Computational prediction of the …

Immune checkpoint inhibitors have been successful across several tumor types; however,
their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where< 10 …

Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with
pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however …

We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-
PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients …

Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome …

Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …